Steven E Come
Overview
Explore the profile of Steven E Come including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
1999
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mostofsky E, Buring J, Come S, Tung N, Zhang C, Mukamal K
Breast Cancer Res
. 2025 Jan;
27(1):5.
PMID: 39789640
Background: Alcohol intake is associated with a higher risk of estrogen receptor-positive (ER+) breast cancer (BC), presumably through its confirmed ability to increase sex hormone levels. Whether consuming alcohol within...
2.
Myers S, Zheng Y, Dibble K, Mittendorf E, King T, Ruddy K, et al.
JAMA Netw Open
. 2024 Nov;
7(11):e2446091.
PMID: 39535790
Importance: Young adults aged 18 to 39 years represent the minority of breast cancer diagnoses but are particularly vulnerable to financial hardship. Factors contributing to sustained financial hardship are unknown....
3.
Sella T, Sorouri K, Rosenberg S, Loucks M, Kirkner G, Snow C, et al.
Cancer
. 2024 Sep;
131(1):e35585.
PMID: 39342485
Background: Following breast cancer (BC), many young women are interested in future childbearing and some may wish to breastfeed. However, limited information is available regarding their lactation experiences. Methods: Participants...
4.
Tesch M, Zheng Y, Rosenberg S, Poorvu P, Ruddy K, Tamimi R, et al.
NPJ Breast Cancer
. 2024 Aug;
10(1):67.
PMID: 39090124
Ovarian function suppression (OFS) benefits young women with hormone receptor (HR)-positive breast cancer but they are at risk for ovarian function breakthrough. We assessed endocrine effects of gonadotropin-releasing hormone agonist...
5.
Vo J, Rosenberg S, Zhang B, Snow C, Kirkner G, Poorvu P, et al.
J Cancer Surviv
. 2024 Jul;
PMID: 39008138
Purpose: Data evaluating cardiovascular disease (CVD) risk by cancer treatment among young women (≤ 40 years) with breast cancer are limited. Methods: Among 372 five-year breast cancer survivors aged 30-40 ...
6.
Zhang B, Brantley K, Rosenberg S, Kirkner G, Collins L, Ruddy K, et al.
Breast Cancer Res Treat
. 2024 Jun;
207(3):587-597.
PMID: 38858235
Purpose: We evaluated the incidence, timing, and risk factors for second primary non-breast cancers (SPNBC) among young breast cancer (BC) survivors. Methods: This study included participants of the Young Women's...
7.
Brantley K, Rosenberg S, Collins L, Ruddy K, Tamimi R, Schapira L, et al.
JAMA Oncol
. 2024 Apr;
10(6):718-725.
PMID: 38602683
Importance: Among women diagnosed with primary breast cancer (BC) at or younger than age 40 years, prior data suggest that their risk of a second primary BC (SPBC) is higher...
8.
Sorouri K, Sella T, Rosenberg S, Loucks M, Kirkner G, Snow C, et al.
Cancer
. 2023 Oct;
130(4):517-529.
PMID: 37880931
Background: Breast cancer (BC) is the most common malignancy in women of reproductive age. This study sought to explore the postcancer conception and pregnancy experience of young BC survivors to...
9.
Lipsyc-Sharf M, Jain E, Collins L, Rosenberg S, Ruddy K, Tamimi R, et al.
JCO Precis Oncol
. 2023 Jun;
7:e2300076.
PMID: 37364233
Purpose: Erb-B2 receptor tyrosine kinase 2 ()-positive breast cancer (BC) is particularly common in young women. Genomic features of -positive tumors before and after chemotherapy and trastuzumab (chemo + H)...
10.
Sella T, Zheng Y, Rosenberg S, Ruddy K, Gelber S, Tamimi R, et al.
NPJ Breast Cancer
. 2023 May;
9(1):31.
PMID: 37185922
Extended adjuvant endocrine therapy (eET) improves outcomes in breast cancer survivors. Most studies however have been limited to postmenopausal women, and optimal eET for young survivors is uncertain. We report...